Pharmaceutical Strategies Group News and Activities

Pharmaceutical Strategies Group is owned by Omnicell.

Omnicell is one of the...

• Russell 3000;
• TOB Iconic 10,000.

Omnicell is a company listed under the stock ticker OMCL (US).

They are in:

• Medical Equipment33%
• Healthcare33%
• Other33%

View the org chart displaying its 7 main executives

Most searched biographies at Pharmaceutical Strategies Group

• Michael Lonergan, President
• Michael Medel, Senior Vice President and Practice Lead, Plan Spons...
• Mike Sackett, Senior Vice President of Financial Analytics, Procur...

Popular executive movements at Omnicell

• Rick Couldry has joined the company as Senior Vice President and Chief Pharmacy and Clinical Officer  (posted on May 2 2026).
• Dave Ford has joined the company as Senior Vice President, Chief People Officer  (posted on December 8 2025).

Create your alert
to follow the executive moves at Pharmaceutical Strategies Group.

Omnicell has 1,912 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Laboratoire Servier has announced the acquisition of Edgewise Therapeutics  (posted on June 4 2026).
• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott
• Jonathan Leff - Director at Larimar Therapeutics

Learn more about the Pharmaceuticals industry

Press releases by Pharmaceutical Strategies Group

• Insights | Pharmaceutical Strategies Group
• Insights | Pharmaceutical Strategies Group
• Pharmaceutical Strategies Group | PSG | State of Specialty Spend and Trend Report Released by Pharmaceutical Strategies Group
• Pharmaceutical Strategies Group | PSG | Trends in Drug Benefit Design Report Released by Pharmaceutical Strategies Group
• Pharmaceutical Strategies Group | PSG | Amjevita, First Biosimilar of Humira, Launches With Two-Tiered Pricing Strategy
• Pharmaceutical Strategies Group | PSG | NEW PRODUCT LAUNCH: PSG Announces Artemetrx Extend
• Pharmaceutical Strategies Group | PSG | Specialty Trend Rose in 2021, but Biosimilars Are Having Impact
• Pharmaceutical Strategies Group | PSG | PSG Announces New Features Designed to Support Biosimilar Strategy
• Pharmaceutical Strategies Group | PSG | Proprietary State of Specialty Spend and Trend Report Released by Pharmaceutical Strategies Group
• Pharmaceutical Strategies Group | PSG | Trends in Drug Benefit Design Report released by Pharmaceutical Strategies Group
• View more press releases Close

Social media about Pharmaceutical Strategies Group

• Pharmaceutical Strategies Group on Wikipedia, Google News & Yahoo Finance
• Pharmaceutical Strategies Group on LinkedIn, X (Twitter) & YouTube